BEKSAÇ, M. Et Al. 2023. Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.. Clinical lymphoma, myeloma & leukemia , vol.23, no.3 .

BEKSAÇ, M., Seval, G., KOYUN, D., TOPÇUOĞLU, P., YÜKSEL, M., GÜRMAN, G., ... İLHAN, O.(2023). Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.. Clinical lymphoma, myeloma & leukemia , vol.23, no.3.

BEKSAÇ, MERAL Et Al. "Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.," Clinical lymphoma, myeloma & leukemia , vol.23, no.3, 2023

BEKSAÇ, MERAL Et Al. "Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.." Clinical lymphoma, myeloma & leukemia , vol.23, no.3, 2023

BEKSAÇ, M. Et Al. (2023) . "Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.." Clinical lymphoma, myeloma & leukemia , vol.23, no.3.

@article{article, author={MERAL BEKSAÇ Et Al. }, title={Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.}, journal={Clinical lymphoma, myeloma & leukemia}, year=2023}